Prävention einer ersten psychotischen Episode

Zusammenfassung

Gegenstand und Ziel: Psychotische Störungen gehören aufgrund ihres frühen Beginns und ihren langfristigen Konsequenzen zu den teuersten psychischen Erkrankungen in Europa. Prävention könnte die gesellschaftlichen Kosten und die immense Belastung für Patienten und Familien signifikant reduzieren. Neurobiologische Befunde deuten auf eine glutamaterge Dysfunktion und ein Redoxungleichgewicht in der Pathophysiologie der Schizophrenie. Wir vermuten, dass Interventionen, die auf soziale Funktionen und glutamaterge /oxidative Signalwege abzielen, die Übergangsraten signifikant reduzieren würden. Material und Methoden: Unsere Studie ist eine randomisierte, placebokontrollierte 18-monatige Studie (6-Monate Intervention; 12 Monate Nachuntersuchung) mit 200 Probanden, die ein klinisch erhöhtes Risiko für Psychosen haben. Wir werden in einem 2x2-faktoriellen Design die präventiven Effekte einer kognitiv-behavioralen und sozial-kognitiven Intervention (IPPI) mit einer pharmakologischen Intervention mit einem pro-glutamatergen, neuroprotektiven Medikament (N-Acetylcystein) vergleichen. Ergebnisse und klinische Relevanz: Die Ergebnisse dieser Studie sollen zu neuen, gut verträglichen präventiven Interventionen führen.

Summary

Objective: Psychotic disorders are among the most expensive brain-related disorders in Europe, due mainly to their onset early in life and their long-term disabling courses. Prevention is expected to significantly reduce the societal costs and the immense burden for the patients and their families. Neurobiological evidence implicates glutamatergic dysfunction and redox imbalance in the pathophysiology of schizophrenia. We hypothesize that interventions targeting social functioning and glutamatergic /oxidative pathways already in at-risk states would significantly reduce transition rates. Material and methods: Our study is a randomized, placebo-controlled, 18- month trial (six months intervention; 12 months follow-up), involving 200 subjects at-risk for psychosis. We will compare in a 2x2 factorial design the preventive effects of a cognitive-behavioural and social-cognitive intervention (IPPI) to a pharmacological intervention with a pro-glutamatergic, neuroprotective drug (N-Acetylcysteine). Results and clinical relevance: The results of this study are expected to provide new and well-tolerated preventive interventions.

Schlüsselwörter

Schizophrenieprodrom - Oxidationsstress - Kombination Pharmakotherapie und Psychotherapie

Keywords

Prodromal schizophrenia - oxidative stress - combined medication and psychotherapy

• Literatur

• 1 Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, just the facts. What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008; 102 (1–3): 1-18.
• 2 Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M. et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39 (06) 1296-306.
• 3 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44 (07) 660-9.
• 4 Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder?. Br Med J 1988; 296 (6614): 63.
• 5 Brown AS. The environment and susceptibility to schizophrenia. Progress in neurobiology 2011; 93 (01) 23-58.
• 6 Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci 2016; 1-9.
• 7 Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22 (02) 353-70.
• 8 Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the Initial Prodromal Phase. Arch Gen Psychiatry 2001; 58 (02) 158-64.
• 9 Campion J, Bhui K, Bhugra D. European Psychiatric Association (EPA) guidance on prevention of mental disorders. Eur Psychiatry 2012; 27 (02) 68-80.
• 10 Seidman LJ, Nordentoft M. New targets for prevention of schizophrenia: Is it time for interventions in the premorbid phase?. Schizophr Bull 2015; 41 (04) 795-800.
• 11 Ruhrmann S, Klosterkötter J, Bodatsch M, Bechdolf A, Graf BSchimmelmann, Nikolaides A. et al. Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 2012; 18 (04) 550-7.
• 12 Mighdoll MI, Tao R, Kleinman JE, Hyde TM. Myelin, myelin-related disorders, and psychosis. Schizophr Res 2015; 161 (01) 85-93.
• 13 Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P. et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007; 104 (42) 16621-6.
• 14 Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34 (03) 167-77.
• 15 Skvarc DR, Dean OM, Byrne LK, Gray L, Lane S, Lewis M. et al. The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. Neurosci Biobehav R 2017; 78: 44-56.
• 16 Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RKR. et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 2015; 30 (03) 405-16.
• 17 van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR. et al. Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Research 2013; 149 (1–3): 56-62.
• 18 Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rössler A. et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015; 30 (03) 388-404.
• 19 Sommer IEC, Slotema CW, Daskalakis ZJ, Derks EM, Blom JD, van der Gaag M. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull 2012; 38 (04) 704-14.
• 20 Thase ME, Kingdon D, Turkington D. The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments. World Psychiatry 2014; 13 (03) 244-50.
• 21 Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168 (05) 472-85.
• 22 Fiszdon JM, Reddy LF. Review of social cognitive treatments for psychosis. Clin Psychol Rev 2012; 32 (08) 724-40.
• 23 Medalia A, Saperstein AM. Does cognitive remediation for schizophrenia improve functional outcomes?. Curr Opin Psychiatry 2013; 26 (02) 151-7.
• 24 Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E. et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003; 84 (05) 1173-83.
• 25 Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 200-6.
• 26 Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M. et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry 2015; 20 (07) 827-38.
• 27 Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010; 65 (05) 585-96.
• 28 Kim HS, Shin NY, Jang JH, Kim E, Shim G, Park HY. et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. Schizophr Res 2011; 130 (1–3): 170-5.
• 29 Granö N, Kallionpää S, Karjalainen M, Edlund V, Saari E, Itkonen A. et al. Lower functioning predicts identification of psychosis risk screening status in help seeking adolescents. Early Intervention in Psychiatry 2015; 09 (05) 363-9.
• 30 Kahn RS, Keefe RSE. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013; 70 (10) 1107-12.
• 31 Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Schlögelhofer M, Mossaheb N. et al. Emotion recognition in individuals at clinical high-risk for schizophrenia. Schizophr Bull 2012; 38 (05) 1030-9.
• 32 Kurtz MM, Richardson CL. Social Cognitive Training for Schizophrenia: A Meta-Analytic Investigation of Controlled Research. Schizophr Bull 2012; 38 (05) 1092-104.
• 33 Gispen-de Wied CC, Jansen LMC. The stress-vulnerability hypothesis in psychotic disorders: Focus on the stress response systems. Curr Psychiatry Rep 2002; 04 (03) 166-70.
• 34 Pruessner M, Iyer SN, Faridi K, Joober R, Malla AK. Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophr Research 2011; 129 (01) 29-35.
• 35 Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I. et al. N-acetyl cysteine as a glutathione precursor for schizophrenia – a doubleblind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64 (05) 361-8.
• 36 Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument, Adult version (SPI-A). Giovanni Fioriti. 2007
• 37 Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J. et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29 (04) 703-15.
• 38 Heinssen RK, Cuthbert BK, Breiling J, Colpe LJ, Dolan-Sewell R. Overcoming barriers to research in early serious mental illness: Issues for future collaboration. Schizophr Bull 2003; 29 (04) 737-45.
• 39 Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry 2015; 09 (03) 200-6.
• 40 Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO. et al. North American prodrome longitudinal study (NAPLS 2): overview and recruitment. Schizophr Research 2012; 142 (1–3): 77-82.
• 41 Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D. et al. The dark side of the moon: Meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull 2016; 42 (03) 732-43.